Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer

Molecular Medicine Reports

Volumn 1, Issue 6, 2008, Pages 925-930

  Nakafusa, Yuji ^a   Tanaka, Masayuki ^a   Ohtsuka, Takao ^a   Miyoshi, Atsushi ^a   Kohya, Naohiko ^a   Kitajima, Yoshihiko ^a   Sato, Seiji ^a   Mochinaga, Sakiko ^b   Dohi, Sawako ^b   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

^b SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Combination chemotherapy; CPT 11; Irinotecan; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; UFT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 69249123310     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000051     Document Type: Article

References (23)

1. Jemal A, Shiegel R, Ward E, Murray T, Xu J and Thum MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Goldberg RM, Sargent DJ, MortonRF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Albert SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
3. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
4. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC and Ahn JB: A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 95: 1637-1641, 2006. (Pubitemid 44950788)
5. Ohtsu A, Baba H, Sakata Y, MitachiY, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000. (Pubitemid 30411708)
6. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H and Sato A: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100: 2355-2361, 2004. (Pubitemid 38657882)
7. Van den Brande J, Schöffski P, Schellens JHM, Roth AD, Duffaud F, Wegang-Köhler, Reinke F, Wanders J, De Boer RF, Vermorken JB and Fumoleau P: EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653, 2003. (Pubitemid 36411437)
8. Kawano Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the comptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 49: 4187-4191, 1991.
9. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Cramichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
10. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta NP, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000. (Pubitemid 30727802)
11. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A and Bussoni R: Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first line treatment in metastatic colorectal carcinoma. Cancer 100: 279-287, 2004. (Pubitemid 38063635)
12. Patt YZ, Lee F-C, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A and Lin E: Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer. Phase II trial results. Am J Clin Oncol 30: 350-357, 2007. (Pubitemid 47356678)
13. Goto A, Yamada H, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y and Sirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17: 968-973, 2006. (Pubitemid 43778988)
14. Yosahimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G and Ogawa K: Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res 27: 1657-1662, 2007. (Pubitemid 46807250)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
16. Yamada Y, Yasui H, Goto A, Arai T, Ura T, Hamaguchi T, Muro K, Shimada Y and Shirao K: Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. Int J Clin Oncol 8: 374-380, 2003. (Pubitemid 38040051)
17. Takiuchi H, Narahara H, Tsujinaka T, Gotoh M, Kawabe S, Katsu K, Ishii H, Tatsuta M, Fujitani K, Furukawa H and Taguchi T: Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol 35: 520-525, 2005. (Pubitemid 41573941)
18. Tsunoda A, Yasuda N, Nakao K, Narita K, Yamazaki K, Watanabe M, Suzuki N and Kusano M: Phase I study S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 72: 58-63, 2007. (Pubitemid 350249130)
19. Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T and Sugihara K: Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 94: 1130-1135, 2006.
20. Katsube T, Ogawa K, Ichikawa W, Fujii M, Tokunaga A, Takagi Y, Kochi M, Hayashi K, Kubota T, Aiba K, Arai K, Terashima M and Kitajima M: Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer. Anticancer Drugs 18: 605-610, 2007. (Pubitemid 46597415)
21. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Miugnard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reversed sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004. (Pubitemid 41095086)
22. Carmichael J, Popiela T, Radstone AD, Falk S, Borner M, Oza A, Skovgaard T, Munier S and Martin C: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627, 2002. (Pubitemid 34983221)
23. Grothey A, Sargent D, Goldberg RM and Schmoll H-J: Survival of patients with advanced colorectal cancer improves with availability of fluorouracil-lucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004. (Pubitemid 41079833)